GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: cardiovascular, rheumatologic
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; BMI ≥25 required; conditions: Psoriasis Arthritis
- Interventions
- Semaglutide 0.5 mg; Semaglutide 1.0 mg; Semaglutide 0.25 mg; No intervention
- Conditions
- Psoriasis Arthritis
- Phase and size
- Phase 4 · 40 participants
- Dates
- Start 2025-12-01
Primary completion 2027-01-01 - Sponsor
- Chinese University of Hong Kong (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Difference in the proportion of subjects with CIMT between the semaglutide group and control group over a period of 24 weeks.24 weeks
02Eligibility
Who can take part
Inclusion Criteria: 1. fulfill the ClASsification criteria for Psoriatic Arthritis, 2. are rheumatoid factor negative, 3. BMI \>=25 kg/m2, 4. are over 18 years old and 5. Chinese subjects Exclusion Criteria: 1. have prior therapy with GLP-1 receptor agonists during the last 24 weeks, 2. have pre-existing diabetes, 3. have liver or renal impairment, 4. have known or symptoms suggestive of CVD, 5. have chronic or previous acute pancreatitis, 6. have current malignancy, 7. are pregnant, breastfeeding or of childbearing potential, or 8. are unable to give written informed consent.
03Change log
Registry changes
No changes recorded since the trial was added.